Evidence map›Paper›PMID 35859161›Full record

ArticleThe ISME journal2022

Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.

Angus M Quinn, Michael J Bottery, Harry Thompson, Ville-Petri Friman

Open access · hybridAbstract read
In one paragraph

Article in The ISME journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Antibiotics (Basel, Switzerland) · 2024
    Review
  7. Co-occurring microflora and mucin driveISME communications · 2024
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Angus M QuinnSchool of Life Sciences, University of Warwick, Coventry, UK. angus.quinn@warwick.ac.uk.ORCID http://orcid.org/0000-0003-1210-3894
Michael J BotteryDepartment of Biology, University of York, York, UK.ORCID http://orcid.org/0000-0001-5790-1756
Harry ThompsonDepartment of Biology, University of York, York, UK.ORCID http://orcid.org/0000-0002-5960-9051
Ville-Petri FrimanDepartment of Biology, University of York, York, UK.ORCID http://orcid.org/0000-0002-1592-157X
University of York · GBUniversity of Manchester · GBUniversity of Warwick · GB

Funding

Biotechnology and Biological Sciences Research Council BB/T010606/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/T00746X/1Royal Society CHL\R1\180031Royal Society RSG\R1\180213Wellcome Trust
6 · The paper itself

Abstract

Antibiotic degrading bacteria can reduce the efficacy of drug treatments by providing antibiotic exposure protection to pathogens. While this has been demonstrated at the ecological timescale, it is unclear how exposure protection might alter and be affected by pathogen antibiotic resistance evolution. Here, we utilised a two-species model cystic fibrosis (CF) community where we evolved the bacterial pathogen Pseudomonas aeruginosa in a range of imipenem concentrations in the absence or presence of Stenotrophomonas maltophilia, which can detoxify the environment by hydrolysing β-lactam antibiotics. We found that P. aeruginosa quickly evolved resistance to imipenem via parallel loss of function mutations in the oprD porin gene. While the level of resistance did not differ between mono- and co-culture treatments, the presence of S. maltophilia increased the rate of imipenem resistance evolution in the four μg/ml imipenem concentration. Unexpectedly, imipenem resistance evolution coincided with the extinction of S. maltophilia due to increased production of pyocyanin, which was cytotoxic to S. maltophilia. Together, our results show that pathogen resistance evolution can disrupt antibiotic exposure protection due to competitive exclusion of the protective species. Such eco-evolutionary feedbacks may help explain changes in the relative abundance of bacterial species within CF communities despite intrinsic resistance to anti-pseudomonal drugs.

Indexed as

Cystic FibrosisPseudomonas InfectionsAnti-Bacterial AgentsHumansImipenemMicrobial Sensitivity TestsPorinsPseudomonas aeruginosaPyocyanineAnti-Bacterial AgentsImipenemPorinsPyocyanine

Identifiers

PMID35859161
PMCPMC9477885
OpenAlexW4286002131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.